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from the expression of healthy controls as well as patients prior to
treatment.Whether up-regulation of tight junction molecules can
be directly associated with the mode of treatment requires further
investigations. Compression therapy may tighten the paracellular
barrier via elevated expression of speci¢c tight junctions and may
prevent the progression of chronic venous insu⁄ciency due to in-
hibited permeability of £uid into the perivascular tissue.
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Figure1. Elevated expression for CLDN-1 and CLDN-5 on mRNA- (A) and protein level (B) after compression therapy in patients with chronic
venous insu⁄ciency (A) Densitometric evaluation of generated mRNA-products of OCLN, CLDN-1, CLDN-3 and CLDN-5 in healthy controls (white
bars), edema patients prior to treatment (crossed bar) and after treatment (black bars). (B) Densitometirc evaluation of immunoblots of OCLN, CLDN-1,
CLDN-3 and CLDN-5 in healthy controls (white bars), venous leg ulcer patients prior to treatment (crossed bar) and after treatment (black bars). Data are
means7SEM (n¼ 8 for healthy skin; n¼ 8 for edema group; n¼ 8 for leg ulcer group). The signi¢cance of di¡erence was determined by an unpaired
student’s t test. Di¡erences were considered signi¢cant at po0.01.
Inhibition of Vascular Cell Adhesion Molecule-1 Expression in
Human Dermal Microvascular Endothelial Cells by Iron
Chelators
To the Editor:
Koo et al (2003) recently reported that iron chelators inhibit tumor
necrosis factor-a-mediated vascular cell adhesion molecule-1 expres-
sion in human dermal microvascular endothelial cells, suggesting
that iron plays a critical role in tumor necrosis factor-a-mediated
vascular cell adhesion molecule-1 induction in these cells. As out-
lined by the authors, these ¢ndings may provide new insights into
the role of iron in the pathogenesis of cutaneous in£ammatory dis-
orders, such as psoriasis, contact dermatitis, and ultraviolet-induced
skin changes. They also support previous studies demonstrating that
topically applied iron chelators provide a high level of photoprotec-
tion in both animal and human testing (Bissett et al, 1994).
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Nevertheless, it may be regrettable to restrict the implication of
these important results to in£ammatory disorders. The adhesive
function of vascular cell adhesion molecule-1 not only facilitates
the binding of leukocytes to activated endothelial cells but is also
used by cancer cells to enhance metastatic implantation and
spread (Rice and Bevilacqua, 1989; Vidal-Vanaclocha et al, 2000).
Moreover, vascular cell adhesion molecule-1 is closely associated
with angiogenesis (Nakao et al, 2003). Iron has also been impli-
cated in the pathogenesis, of cancers and several clinical observa-
tions have been made linking cellular iron content to the
development of cancers in humans (Weinberg, 1996). The metal
is carcinogenic owing to its catalytic e¡ect on the formation of
hydroxyl radicals, suppression of the activity of host defense cells,
and promotion of cancer cell multiplication (Weinberg, 1996).
Based on this possible role of iron in tumor development, several
studies have suggested a potential antitumor activity of iron che-
lation and have shown that iron deprivation induces apoptosis of
various proliferating cell types (Richardson, 2002; Simonart et al,
2002).We previously showed that exposure of human dermal mi-
crovascular endothelial cells to the iron chelator 10 to 100 mM des-
ferrioxamine for less than 24 h did not signi¢cantly reduce the
number of cells excluding Trypan blue dye (Simonart et al,
2000), which is in line with the results reported by Koo et al
(2003). Nevertheless, this signi¢cantly a¡ected the clonogenic sur-
vival of human dermal microvascular endothelial cells (Simonart
et al, 2000), indicating a possible latent toxicity of the drug, which
was evidenced by massive apoptosis of the cells after 72 h of ex-
posure to desferrioxamine at concentrations 10 times lower than
those used by Koo and colleagues. Because in£ammatory en-
dothelial responses may be inhibited during apoptotic stimuli
(Neuzil et al, 2001), it remains to be determined whether distinct
mechanisms are responsible for the anti-in£ammatory and pro-
apoptotic e¡ects of iron chelators in endothelial cells. Neverthe-
less, the results reported by Koo et al may further suggest that the
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